SOUTH SAN FRANCISCO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2006 and Quarterly Reports on Form 10-Q for the first three quarters of 2006. The reports can be found at the link titled "SEC Filings" in the Investor Relations section of VaxGen's web site at http://www.vaxgen.com.
The only financial statements the company has outstanding before it regains compliance with its SEC financial reporting obligations are the Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2007, both of which are under review by VaxGen and its independent auditors. Once VaxGen is current with its financial statements, the company intends to apply for listing on a national stock exchange.
VaxGen's estimated cash, cash equivalents and short-term investments totaled $85.7 million as of the end of the company's most recent quarter on June 30, 2007.
VaxGen, Inc. is a biopharmaceutical company located in South San Francisco. For more information, please visit the company's web site at http://www.vaxgen.com.
Note: This press release contains "forward-looking statements" within
the meaning of the federal securities laws. These forward-looking
statements include without limitation, statements regarding the anticipated
filing of the company's outstanding quarterly reports and its application
for listing of its common stock. These statements are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated. Readers are cautioned not to place undue
reliance on t
|SOURCE VaxGen, Inc.|
Copyright©2007 PR Newswire.
All rights reserved